Corcept Therapeutics Incorporated research snapshot
CORT AI stock analysis currently reads Corcept Therapeutics as a commercial-stage cortisol-modulation company moving from a one-product Cushing’s business toward a broader oncology and endocrine platform. At the July 12, 2026 data cutoff, the latest verified market close was $91.88 on July 10, the calculated market capitalization was about $9.86 billion, and the stock was near its 52-week high after Lifyorli approval and the resubmission of relacorilant for Cushing’s syndrome. The opportunity is real, but the valuation already requires a successful launch, better earnings, and further regulatory progress. This page is informational research, not investment advice.
Current price
$91.88 close on July 10, 2026
Market cap
$9.86 billion
AI score
62 / 100
Rating
Commercial-stage biotech with a real revenue base, but high launch and regulatory risk
Trend status
Strong uptrend, overbought near the 52-week high
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Corcept sells cortisol-modulating medicines and funds a growing research platform from Korlym revenue. Lifyorli adds a second approved product and a new oncology market, but the commercial base is still concentrated. | Medium-high |
| Moat | The moat is specialized cortisol biology, clinical know-how, patents, physician education, and rare-disease commercial infrastructure. It is narrower than a network-effect moat and can weaken through generic competition or failed trials. | Medium |
| Management | CEO and President Joseph K. Belanoff and CFO Atabak Mokari are steering a cash-generating company through a costly launch and a broad pipeline. Officers and directors owned about 21% of the common stock as of February 17, 2026, aligning incentives but also concentrating influence. | Medium-high |
| Financial trend | FY2025 revenue rose to $761.4 million, while net income fell to $99.7 million. Q1 2026 revenue reached $164.9 million, but launch and growth spending produced a $31.8 million net loss. | High |
| Valuation | At $91.88, CORT traded near 229.7x TTM EPS, 12.8x TTM sales, and 82.0x TTM free cash flow. The market is valuing the earnings inflection from Lifyorli and the pipeline, not just the current Korlym cash flow. | High |
| Technical trend | Price was above the reported 50-day moving average of $71.00 and 200-day moving average of $60.97, with RSI near 74.6 and price close to the $95.11 52-week high. Momentum is strong, but the setup is extended. | Medium-high |
| Risk level | Risk is high because product launch execution, FDA decisions, trial readouts, Korlym generic competition, gross-to-net rebates, legal matters, and valuation can all move the stock materially. | High |
| AI confidence | AI confidence is high for descriptive filings and published regulatory events, and medium for scenario outcomes that depend on clinical, commercial, and market variables. | High data confidence |
| Investment certainty | Investment certainty is below the data confidence because CORT needs a successful oncology launch and continued clinical progress to justify its current multiple. | Medium-low |
CORT AI stock forecast
The CORT AI stock forecast is a scenario framework, not a price promise. Using FY2025 diluted EPS of $0.82 as a normalized starting point, the audited three-year model returned an illustrative bullish value near $124.5, a base value near $54.0, and a bearish value near $10.1. The ranges below are wider because launch adoption, FDA review, clinical data, and biotech valuation multiples can change quickly.
$105 to $135
More likely if Lifyorli becomes a meaningful commercial product, the Cushing’s NDA is accepted and approved after its June 2026 resubmission, Korlym demand holds despite generics, pipeline readouts remain positive, and earnings compound near 50% with a premium 45x multiple.
$45 to $65
More likely if Lifyorli launches gradually, Cushing’s review takes time, operating expenses stay elevated, revenue grows but earnings normalize more slowly, and the market values a three-year earnings profile near a 30x multiple.
$8 to $20
More likely if Lifyorli uptake disappoints, relacorilant receives another regulatory setback, Korlym pricing and volume fall, pipeline trials fail, or investors apply a lower multiple to declining earnings and high development costs.
CORT AI technical analysis
CORT AI technical analysis is constructive but extended as of the July 12, 2026 cutoff. The July 10 close was above the reported 50-day average of $71.00 and 200-day average of $60.97. RSI was 74.58, average 20-day volume was about 1.03 million shares, and the 52-week range was $28.66 to $95.11. Confirm levels on a live chart because this page uses static data.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $91.88 | NASDAQ close on July 10, 2026, used for the market cap and valuation calculations at the July 12 cutoff. |
| Near support | $81.75 to $83.71 | Recent June closing levels formed the nearest visible pullback reference before the July breakout extension. |
| 50-day moving average | $71.00 | A close below this reported moving average would weaken the near-term trend and increase mean-reversion risk. |
| 200-day moving average | $60.97 | This is the longer-term trend filter from the July 2026 technical snapshot. |
| Near resistance | $95.11 | The reported 52-week high is the first overhead level. A breakout needs follow-through rather than a single event-driven spike. |
| Secondary resistance | $100.00 | This round-number level can become a psychological supply area if price clears the 52-week high. |
| Momentum | RSI 74.58, positive but overbought | Price strength is supported by the move above both moving averages, while the high RSI raises pullback risk. |
| Volume | About 1.03 million shares average over 20 days | Breakouts and reversals are more credible when volume expands relative to this reference. |
| Volatility | Beta 0.46, with biotech event risk | Beta has been below the market average, but FDA decisions and clinical readouts can produce gaps that beta does not capture. |
| Invalidation | Close below $71, then $60.97 | A break below the 50-day average weakens the short-term setup. A sustained break below the 200-day average challenges the longer-term trend. |
CORT AI trading strategy
The CORT AI trading strategy is a rules-based research framework, not personalized advice. It combines price confirmation with launch metrics, regulatory milestones, cash use, and position sizing because a single clinical or FDA headline can overwhelm ordinary chart signals.
Watch for price to hold above the $71.00 50-day average and clear the $95.11 52-week high with expanding volume. A failed breakout is less informative than a close back below the breakout area.
Use a predefined invalidation level and reduce exposure if price closes below the 50-day average or if launch data contradicts the clinical thesis.
If CORT pulls back toward the 50-day average without a new regulatory or clinical problem, compare price action with Lifyorli prescriptions, Korlym volume, revenue guidance, and cash and investment balances.
Do not average down solely because the share price fell. A failed FDA path or weak launch can make historical support levels irrelevant.
Track Lifyorli launch revenue, patient starts, payer access, Korlym and authorized generic mix, gross-to-net rebates, operating expenses, Q2 2026 results, Cushing’s NDA review, BELLA and MONARCH readouts, and any ALS Phase 3 update.
Lower confidence if growth depends on higher spending without revenue conversion, if cash declines faster than expected, if share count rises, or if a trial or regulatory result changes the addressable market.
Investment research summary
Corcept is a cortisol-modulation company. Customers and patients pay for Korlym in a specialized Cushing’s syndrome use case, while Lifyorli adds an approved oncology product used with nab-paclitaxel for platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer. The economic model is high gross margin with substantial research, sales, and regulatory spending.
The moat comes from selective glucocorticoid receptor science, accumulated clinical data, patents, physician education, patient-support infrastructure, and experience navigating rare endocrine markets. It is not a network effect. Teva generic competition for Korlym and the need to prove each new indication can narrow it.
The thesis fails if Lifyorli does not convert approval into durable sales, Cushing’s relacorilant cannot clear the FDA after the CRL and resubmission, Korlym pricing falls faster than volume grows, clinical trials disappoint, or legal and reimbursement issues consume the cash balance. A high multiple magnifies each disappointment.
Management has built a profitable commercial base, changed the specialty pharmacy vendor after 2025 capacity constraints, funded a broad cortisol pipeline, and repurchased $172.9 million of stock under the program in 2025. The key test is whether capital shifts from the legacy product toward Lifyorli and pipeline opportunities without weakening per-share value.
CORT sits at the intersection of rare endocrine disease, oncology, and cortisol biology. The long-term opportunity is a broader use of glucocorticoid receptor antagonism, but the company must earn each market through clinical evidence, regulatory approval, reimbursement, and physician adoption. This is a scientific and regulatory trend, not a guaranteed market expansion.
At roughly $9.86 billion of market value, 12.8x TTM sales, and 82.0x TTM free cash flow, CORT is priced for an earnings inflection rather than current profitability. Cash and investments provide balance-sheet support, but they do not create a margin of safety if Lifyorli or the pipeline fails to replace the market’s growth assumptions.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CORT price | $91.88 close on July 10, 2026 | StockAnalysis market snapshot and history | July 12, 2026 |
| Market capitalization | $9.86 billion, verified as $91.88 x 107.351594 million shares | StockAnalysis and SEC 10-Q, checked with financial_rigor.py | July 12, 2026 |
| Shares outstanding | 107.351594 million on April 23, 2026 | Corcept Q1 2026 Form 10-Q and StockAnalysis | July 12, 2026 |
| FY2025 product revenue | $761.407 million, up from $675.040 million in 2024 | Corcept FY2025 Form 10-K, cross-checked with StockAnalysis and Macrotrends | July 12, 2026 |
| FY2025 net income | $99.652 million, with $98.171 million attributable to common stockholders | Corcept FY2025 Form 10-K, cross-checked with StockAnalysis and Macrotrends | July 12, 2026 |
| Q1 2026 revenue and net loss | $164.903 million revenue and $31.761 million net loss | Corcept Q1 2026 Form 10-Q and earnings release | July 12, 2026 |
| Cash and investments | $515.4 million at March 31, 2026, compared with $532.4 million at December 31, 2025 | Corcept Q1 2026 Form 10-Q and earnings release | July 12, 2026 |
| TTM free cash flow | $119.79 million, or about $1.12 per share in the latest statistics snapshot | StockAnalysis cash flow and statistics pages | July 12, 2026 |
| Current valuation snapshot | About 229.7x TTM EPS, 15.47x book, 82.04x FCF, and 12.83x sales from verified inputs | financial_rigor.py valuation verification and StockAnalysis ratios | July 12, 2026 |
| Lifyorli approval | FDA approved relacorilant plus nab-paclitaxel on March 25, 2026 for eligible platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer | U.S. Food and Drug Administration | July 12, 2026 |
| Cushing’s NDA status | Relacorilant NDA resubmitted on June 17, 2026 with additional analyses requested by the FDA; Corcept expects a six-month review | Corcept corporate release | July 12, 2026 |
| Technical snapshot | 50-day average $71.00, 200-day average $60.97, RSI 74.58, beta 0.46, 52-week range $28.66 to $95.11 | StockAnalysis statistics page | July 12, 2026 |
This CORT AI stock analysis is an informational tool, not investment advice, a recommendation, or a promise of returns. Forecast ranges are scenario estimates based on available data and stated assumptions. Clinical, regulatory, financial, technical, and market conditions can change, and the analysis may be wrong. Verify current data and consult a qualified professional before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
